skip to main content

S. 2535 (115th): Opioid Quota Reform Act

We don’t have a summary available yet.

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress, and was published on Mar 12, 2018.

Opioid Quota Reform Act

This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone.

Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.